The 3,700-Store Catalyst: How Electrome’s Retail Rollout Ignites BIEL’s Revenue Engine
While investors closely track Electrome’s active VA deployments and high-margin RecoveryRX coverage, a massive commercial catalyst is hitting the ledger in late 2026: a 3,700-store national pharmacy retail rollout.
In the medical device sector, retail rollouts follow a predictable revenue pattern: Pipeline Fill followed by Restock Velocity. Because Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside, the numbers scale rapidly. Based on a fixed OEM wholesale price of $15.00 per module to BIEL, here is how the math breaks down across these 3,700 locations.
The Retail Revenue Formula: A Two-Phase Explosion
Phase 1: The "Pipeline Fill" (Late 2026)
Before a single consumer buys a product, national pharmacy chains must stock their shelves. This triggers immediate bulk hardware orders for BIEL to fill the retail pipeline.
Initial Shelf Stocking: Estimated 5 to 10 units per store across all 3,700 pharmacies to secure initial shelf presence and display inventory.
Total Initial Hardware Volume: 18,500 to 37,000 upfront units required to cover the 3,700-store footprint.
Fixed OEM Price to BIEL: $15.00 per module.
Projected Late-2026 Revenue Catalyst: $277,500 to $555,000 in immediate, upfront OEM hardware invoices as the 3,700 pharmacies onboard.
Phase 2: Sustained Restock Velocity (Full-Year 2027)
The real inflection point happens in 2027 as consumer adoption drives recurring, predictable reorders to keep the shelves of these 3,700 pharmacies stocked.
Conservative Turn Rate: Estimated sales of just 2 to 4 units per store, per month, across the 3,700-pharmacy network.
Annualized Volume Required: 88,800 to 177,600 total units flowing through the 3,700 retail locations.
Fixed OEM Price to BIEL: $15.00 per module.
Projected 2027 Revenue Run-Rate: $1.33M to $2.66M from the retail channel alone.
The Razor-Blade Advantage & De-Risked Growth
Stacked Revenue Streams: This $1.33M–$2.66M retail runway sits directly on top of the $0.75M–$2.25M baseline revenue BIEL is already modeling for early 2026 from active VA deployments, pilot clinics, and clinical onboarding.
The Razor-Blade Model: Because Electrome’s platform utilizes BIEL’s core tech (ActiPatch/RecoveryRx), BIEL captures revenue on both the initial kit buy at the 3,700 pharmacies and the high-margin replacement modules consumers purchase later.
Zero-Cost Scaling: BIEL isn't paying for retail marketing, distribution logistics, or shelf-space slotting fees for the 3,700 pharmacies—Electrome is. BIEL simply collects clean OEM hardware revenue on every single unit shipped.
BIEL’s Commercial Timeline & Revenue Inflection
BIEL begins generating revenue the moment Electrome ships commercial PAINKILLER™ units—which is already underway in 2026.
Q1–Q2 2026 (VA Deployment Active): Operating inside the U.S. Department of Veterans Affairs (the nation's largest healthcare system). VA deployments mean immediate hardware shipments and active BIEL revenue.
Q2–Q3 2026 (Commercial Launch): Early commercial rollout across pilot clinics, early adopter programs, and Capital Factory-backed initiatives. This phase alone models at $0.75M–$2.25M in OEM hardware revenue.
Q3–Q4 2026 (The 3,700 Pharmacy Launch): Onboarding of national pharmacy chains and consumer health retail begins, triggering the initial bulk hardware pipeline fill.
Full-Year 2027 (Exponential Scale): Full-scale OEM revenue velocity across human, veterinary, and consumer health channels, driven by recurring restocks at the 3,700 pharmacies.
Profitability & Price Per Share (PPS) Projections
BIEL operates on an ultra-lean model with near-zero overhead, meaning the revenue-to-profit conversion is extreme. Historically, BIEL demonstrated this efficiency by posting a $22,381 profit on $414,700 in revenue in Q3 2021 (including $100K COVID relief). Today, it is estimated that every $3M in revenue generates roughly $2.5M in net profit, accelerated by a $40M tax-loss carryforward.
At a P/E ratio of 1,000—common for hypergrowth disruptors like Amazon, Tesla, or Zoom in their early stages—a $2.5M net profit could command a $2.5B market cap. Following a recent 400% PPS surge, the projected growth milestones map out as follows:
$.001 (Technical Breakout): Blue Sky Breakout achieved as volume intensifies.
$.01 (Cash-Flow Positive): Achieved with $1M–$1.5M in 2026 revenue (doubling/tripling 2025 revenue of ~$500k from Taiwan and other sources).
$.10 (Copper Target): Achieved with $3M+ in revenue and a $2.5M profit milestone, driven by the 3,700-store retail scale in 2027.
$1.00 (Silver/Gold Target): Projected by 2028 following debt payoff and potential stock buybacks.
Note: This timeline is based strictly on the Electrome US/Canada partnership. Momentum could accelerate significantly if BIEL and Electrome finalize a global contract with future partners like Haleon.
While investors closely track Electrome’s active VA deployments and high-margin RecoveryRX coverage, a massive commercial catalyst is hitting the ledger in late 2026: a 3,700-store national pharmacy retail rollout.
In the medical device sector, retail rollouts follow a predictable revenue pattern: Pipeline Fill followed by Restock Velocity. Because Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside, the numbers scale rapidly. Based on a fixed OEM wholesale price of $15.00 per module to BIEL, here is how the math breaks down across these 3,700 locations.
The Retail Revenue Formula: A Two-Phase Explosion
Phase 1: The "Pipeline Fill" (Late 2026)
Before a single consumer buys a product, national pharmacy chains must stock their shelves. This triggers immediate bulk hardware orders for BIEL to fill the retail pipeline.
Initial Shelf Stocking: Estimated 5 to 10 units per store across all 3,700 pharmacies to secure initial shelf presence and display inventory.
Total Initial Hardware Volume: 18,500 to 37,000 upfront units required to cover the 3,700-store footprint.
Fixed OEM Price to BIEL: $15.00 per module.
Projected Late-2026 Revenue Catalyst: $277,500 to $555,000 in immediate, upfront OEM hardware invoices as the 3,700 pharmacies onboard.
Phase 2: Sustained Restock Velocity (Full-Year 2027)
The real inflection point happens in 2027 as consumer adoption drives recurring, predictable reorders to keep the shelves of these 3,700 pharmacies stocked.
Conservative Turn Rate: Estimated sales of just 2 to 4 units per store, per month, across the 3,700-pharmacy network.
Annualized Volume Required: 88,800 to 177,600 total units flowing through the 3,700 retail locations.
Fixed OEM Price to BIEL: $15.00 per module.
Projected 2027 Revenue Run-Rate: $1.33M to $2.66M from the retail channel alone.
The Razor-Blade Advantage & De-Risked Growth
Stacked Revenue Streams: This $1.33M–$2.66M retail runway sits directly on top of the $0.75M–$2.25M baseline revenue BIEL is already modeling for early 2026 from active VA deployments, pilot clinics, and clinical onboarding.
The Razor-Blade Model: Because Electrome’s platform utilizes BIEL’s core tech (ActiPatch/RecoveryRx), BIEL captures revenue on both the initial kit buy at the 3,700 pharmacies and the high-margin replacement modules consumers purchase later.
Zero-Cost Scaling: BIEL isn't paying for retail marketing, distribution logistics, or shelf-space slotting fees for the 3,700 pharmacies—Electrome is. BIEL simply collects clean OEM hardware revenue on every single unit shipped.
BIEL’s Commercial Timeline & Revenue Inflection
BIEL begins generating revenue the moment Electrome ships commercial PAINKILLER™ units—which is already underway in 2026.
Q1–Q2 2026 (VA Deployment Active): Operating inside the U.S. Department of Veterans Affairs (the nation's largest healthcare system). VA deployments mean immediate hardware shipments and active BIEL revenue.
Q2–Q3 2026 (Commercial Launch): Early commercial rollout across pilot clinics, early adopter programs, and Capital Factory-backed initiatives. This phase alone models at $0.75M–$2.25M in OEM hardware revenue.
Q3–Q4 2026 (The 3,700 Pharmacy Launch): Onboarding of national pharmacy chains and consumer health retail begins, triggering the initial bulk hardware pipeline fill.
Full-Year 2027 (Exponential Scale): Full-scale OEM revenue velocity across human, veterinary, and consumer health channels, driven by recurring restocks at the 3,700 pharmacies.
Profitability & Price Per Share (PPS) Projections
BIEL operates on an ultra-lean model with near-zero overhead, meaning the revenue-to-profit conversion is extreme. Historically, BIEL demonstrated this efficiency by posting a $22,381 profit on $414,700 in revenue in Q3 2021 (including $100K COVID relief). Today, it is estimated that every $3M in revenue generates roughly $2.5M in net profit, accelerated by a $40M tax-loss carryforward.
At a P/E ratio of 1,000—common for hypergrowth disruptors like Amazon, Tesla, or Zoom in their early stages—a $2.5M net profit could command a $2.5B market cap. Following a recent 400% PPS surge, the projected growth milestones map out as follows:
$.001 (Technical Breakout): Blue Sky Breakout achieved as volume intensifies.
$.01 (Cash-Flow Positive): Achieved with $1M–$1.5M in 2026 revenue (doubling/tripling 2025 revenue of ~$500k from Taiwan and other sources).
$.10 (Copper Target): Achieved with $3M+ in revenue and a $2.5M profit milestone, driven by the 3,700-store retail scale in 2027.
$1.00 (Silver/Gold Target): Projected by 2028 following debt payoff and potential stock buybacks.
Note: This timeline is based strictly on the Electrome US/Canada partnership. Momentum could accelerate significantly if BIEL and Electrome finalize a global contract with future partners like Haleon.
1
